Komori
KYORIN Pharmaceutical (4569) · InitiativeFirst stated

Change in the Term of the Mesalazine Distribution Agreement

First written in FY2022-Q1. . Latest entry: FY2022-Q1.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Change to the term of the mesalazine sales agreement with 日清ファルマA theme 1 companies write about · 0 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2022-Q1First statedAnnual report

    「Domestic distribution agreement (in-licensing); contracting company: KYORIN Pharmaceutical Co.,Ltd. (consolidated subsidiary); product: mesalazine; counterparty: Nisshin Pharma Inc.; contract year: 2008; term: through 10 July 2023.」

    The term of the mesalazine distribution agreement with Nisshin Pharma was disclosed as ending on 10 July 2023.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.